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Background: Chronic lymphocytic leukemia (CLL) is an incurable malignancy of
mature B-lymphocytes, characterized as being a heterogeneous disease with variable
clinical manifestation and survival. Mutational statuses of rearranged immunoglobulin
heavy chain variable (IGVH) genes has been consider one of the most important
prognostic factors in CLL, but despite of its proven value to predict the course of the
disease, the regulatory programs and biological mechanisms responsible for the
differences in clinical behavior are poorly understood.
Methods: In this study, (i) we performed differential gene expression analysis
between the IGVH statuses using multiple and independent CLL cohorts in
microarrays platforms, based on this information, (ii) we constructed a simplified
protein-protein interaction (PPI) network and (iii) investigated its structure and
critical genes. This provided the basis to (iv) develop a Boolean model, (v) infer
biological regulatory mechanism and (vi) performed perturbation simulations in
order to analyze the network in dynamic state.
Results: The result of topological analysis and the Boolean model showed that the
transcriptional relationships of IGVH mutational status were determined by specific
regulatory proteins (PTEN, FOS, EGR1, TNF, TGFBR3, IFGR2 and LPL). The dynamics
of the network was controlled by attractors whose genes were involved in
multiple and diverse signaling pathways, which may suggest a variety of
mechanisms related with progression occurring over time in the disease. The
overexpression of FOS and TNF fixed the fate of the system as they can activate
important genes implicated in the regulation of process of adhesion, apoptosis,
immune response, cell proliferation and other signaling pathways related with
cancer.
Conclusion: The differences in prognosis prediction of the IGVH mutational status
are related with several regulatory hubs that determine the dynamic of the system.
Keywords: CLL, PPI network, Boolean network, Topological analysisBackground
Chronic lymphocytic leukemia (CLL), the most common type of adult leukemia in de-
veloped countries, is an incurable malignancy of mature B lymphocytes, characterized
by accumulation of mature B cells in the blood, bone marrow, and secondary lymphoid
organs such as the lymph nodes (LN) [1, 2]. Patients with CLL show a highly variable© 2015 Alvarez-Silva et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
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evolutionary dynamics of sub-clonal mutations [3]. Investigations of the B cell receptor
(BCR) indicate that 60–65 % of CLLs carry immunoglobulin heavy chain variable (IGHV)
genes with evidence of somatic hypermutation and this may modify BCR affinity for
antigens. Conversely, 35–40 % of CLLs are devoid of IGHV somatic mutations [4].
Understanding the pathological mechanisms of CLL has helped to divide the disease
into two risk categories that have a strong impact on prognosis and treatment: 1)
patients with minimal clinical manifestations and 2) an aggressive form characterized
by high mortality, whose IGHV genes can be somatically mutated or unmutated,
respectively. Due to the importance of IGVH status in the determination of the course
of the disease, several expression studies have focused on the comparison of CLL type
mutated IGVH vs. IGVH unmutated. Nevertheless, these studies have identified genes
that are not functionally related and therefore cannot elucidate biological mechanisms
to distinguish between risk categories.
The interactions of proteins are essential to execute biological functions in different
contexts [5]. Since cancer is a complex and multi-factorial disease involving diverse
anomalies, the representation and analysis of a malignant cell as a protein-protein
interaction (PPI) network can provide insights into its behavior. It has been postulated
that proteins with high connectivity within a PPI network could represent meaningful
biological information, despite non-being differentially expressed [6]. Thus, the inte-
grated analysis of gene expression data with PPI networks could be valuable method to
provide knowledge into molecular mechanisms of diseases. The analyses of PPI
networks have varied applications such as identification of drug targets, functional
protein modules and disease candidate genes [7, 8].
On the other hand, dynamic network modeling can be used to gain insight into the
functionality of biological processed and made possible simulations to predict models
behavior [9]. Modeling of regulatory networks as dynamical systems includes modeling
based on ordinary differential equations [10, 11], Bayesian framework [12] and Boolean
rules [13, 14]. Given the limitation of quantitative models that need knowledge on the
kinetics and mechanistic parameters of the system, in addition of a wealth of qualitative
and interaction data obtained from the experimental literature and high-throughput
technologies, the qualitative approaches such as Boolean modeling become an ex-
tremely useful resource [15].
The Boolean modeling considers the genes as binary variables being either active or
passive, but encompassing the essential functionality of the system, the general building
blocks that have been identified in Boolean networks constitute different types of
robust switching elements [16]. This type of approach is already successfully applied in
complex models as the FA/BRCA pathway in Fanconi anemia [17], the survival process
of in large granular lymphocyte leukemia [18], process of T-helper lymphocytes [19]
and the control of the mammalian cell cycle [20].
In this study, we constructed a simplified PPI network of the IGVH mutational status
in CLL and analyzed its structure and critical genes. We used the topology of the
network to develop a Boolean model, infer regulatory mechanisms and perform
simulations to analyze the network in dynamic state. The modeling of the PPI network
led to identify regulatory elements of the disease, contributing to understand the prog-
nostic differences and the dynamic behavior under different perturbations over time.
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We inquired into the impact of differentially expressed genes (DEG) between the IGVH
statuses by mapping them onto the PPI network. The initial data set of 502 DE genes
was reduced to 90 genes with the software STRING and exhaustive literature
reviewed. The PPI network reconstructed contains 90 nodes and 120 regulatory edges
(Fig. 1). An additional table shows the functions of all genes implicated in the network
(Additional file 1: Table S1). The resulting simplified network made evident that DEG
between IGVH statuses are not always represented by highly connected nodes.
The main topological characteristic of the network is the degree distribution P(k), which
tells us the probability that a select node has exactly k links. The degree distribution P(k)
allows us to distinguish between different types of biological networks. We obtained a
power-law degree distribution which characterize scale free networks (Fig. 2), where the
probability that a node displays k links follows P(k) ∼ k− γ, where γ is the degree exponent
that describes the role of the hubs in the system [21]. In the PPI network we obtained
values of γ between 2 and 3, indicating that there exist a hierarchy of hubs, i.e. there are a
large number of nodes with few connections while highly connected nodes are scarce
[21]. The following genes showed the highest values in degree evaluation: in-degree
(PTEN, FOS, and EGR1) and out-degree (TNF, TGFBR3, and IFGR2). Values of γ between
2 and 3 refer also to the small-world property [22], characterized by a small value of diam-
eter, which increase the network efficiency. However, we obtained a value of diameter of
8, greater-than-expected for networks with the small-world property. To explain the
values of diameter higher to the expected, Zhang et al. [22] made a comparison between
the values of diameter reported for real biological networks regarding to diameters ob-
tained for networks with the same features in which the connections between nodes are
randomized. Specifically, they evaluated the diameter of protein-protein interactionFig. 1 Protein-protein interaction network. Pink edges: inhibition. Green edges: activation. Purple nodes: low























Fig. 2 a. Power-law in-degree distribution b. Power-law out-degree distribution
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Their simulation showed that an increment of the diameter in the real networks allows a
significant increase of the network modularity, suggesting an adjustment between network
efficiency and the benefits obtainable by modularity [22].
This analysis was completed by other centralities measures such as closeness and be-
tweenness, which provide a characterization of nodes that are relevant for the network
structure. Closeness is defined by the inverse of the average length of the shortest paths
to all other nodes [23]. We found TNF, TGFBR3, and IFGR2 as proteins with the high-
est closeness values in the PPI network. A protein with high closeness, compared to
the average closeness of the network, will be easily central to the regulation of other
proteins but with some proteins not influenced by its activity [24]. Implying that those
proteins are the closest to all other nodes and have an extent of influences on the entire
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formation to spread from a given node to others [25]. Betweenness is defined by the
number of shortest paths that pass through a node [26]. The betweenness index favors
nodes that join communities rather than nodes that lie inside a community [27, 28].
FOS, TNF and LPL exhibited the highest values, implying a role as linkers in the
control of interactions between proteins. Selected genes, reported above, can be seen
in Fig. 3. The overall parameters that characterized the network are shown in the
Additional file 2: Table S2, and the topological parameters for each one of the nodes
are shown in the Additional file 3: Table S3.
We saw that centrality measures in the PPI network shown some degrees of overlap,
stressing the importance of the implicated proteins in the system structure. According
to Yu et al. [29], as a complementary notion of highly connected proteins known as
hubs proteins, it is possible to define bottlenecks proteins as proteins with high be-
tweenness values, bottlenecks proteins are essential connectors with surprising func-
tional and dynamic properties. Therefore, to develop a Boolean model and evaluate the
genes with influence in the behavior of the network over time, we focused on those that
were at the center of the major structural hubs and simultaneously exhibited the highest
values in the topological centralities evaluated. The selected nodes were: FOS, PTEN,
TGFBR3, and TNF. The dependencies between the genes obtained from the literature re-
view were translated to rule sets. The biological events for activation or inhibition were
qualitatively represented by Boolean functions, that is, combinations of AND, OR, and
NOT operations, that determine the evolution of a node through time and their relation
to the other components of the system (Additional file 4: Table S4).
Starting from an initial condition, the Boolean model evolved over time to finally
stabilizes in a recurrent state known as attractor, representing the long-term behavior
of the system [15]. We found a simple attractor for the PPI network for CLL consisting
of one state. The model obtained achieves the fixed point (steady state) after six time
steps. The state of transition and its successor attractor (starting from the initial state
determined by microarray analysis) are shown in Fig. 4. Starting from 50 random initial
states, the system had both the single-state attractors and cycle attractors. The major
cycle attractors displayed four states (Fig. 5). This showed important dependency of the
achieved attractor according to the initial system state.
Given the relevance of signaling pathways as triggers of processes associated with
cancer oncogenesis and progression, the activated proteins in the attractor were
subjected to modular functional enrichment to determine annotations from KEGG and
Panther pathways simultaneously. The associated annotations involved various
pathways related to cancer with statistical significance for focal adhesion (corrected p
value = 0.000231747). Other signaling pathways detected in the attractor included: B
cell receptor, T cell receptor, cytokine-cytokine, integrin, and cadherin, among others.
Processes related with cell proliferation and regulations of transcription were also
present.
Given the overriding importance attributed to FOS and TNF in cancer biology and
their high topological measures in the PPI network, we chose these genes to performed
perturbation simulations of knockout and overexpression in the system. Furthermore,
we analyzed the effect of different initial conditions that can lead the system to different
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Fig. 3 Measure of centralities of FOS, TNF, PTEN and TGFBR3
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nodes were active.
The overexpression of FOS produced activation of genes related with multiples sig-
naling pathways. When comparing activated genes under the FOS overexpression re-
gardless of activated genes in the original attractor, the modular functional analysis
found the MAPK signaling pathway with the most significant value, (p = 4.37211e-05).
Other pathways involved were: apoptosis (p = 7.34148e-05), PDGF (p = 0.000100226),
JAK-STAT (p = 0.0001216), angiogenesis (p = 0.0001216) and cytokine-cytokine inter-
action (p = 0.000500178). Similarly, activated genes under TNF overexpression were
involved in multiple signaling pathways associated with cancer: focal adhesion (p =
7.05488e-07), angiogenesis (p = 8.39556e-07), JAK-STAT (p = 1.39118e-06), tight junc-
tion (p = 5.76719e-06), MAPK (p = 7.60619e-06), Wnt (p = 0.000105245), among others.
Under both initial conditions the effect of knocking out of any gene did not display
an effect, since the same attractor was obtained when no gene was knocked out. Never-
theless, the path length to achieve the attractor varies significantly, that is, depending
on the initial conditions, the system takes more or less steps of evolution in time to
stabilize in a recurrent state, known as attractor. From this behavior of the system, it
can be concluded that the attractor achieved is the most stable state of the network,
because although there are perturbations involving the system, the network returns to
the same steady state after different steps of time evolution.
On the other hand, when constantly maintaining the major nodes active under the
two initial conditions studied, we found that the selected gene displayed an effect on
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Fig. 4 Visualization of a sequence of states. a. The columns of the table represent consecutive states of the
time series. b. Steady-state attractor of the network from initial state determined by microarray analysis. Genes
are encoded in the following order: AEBP1 AFF1 AICDA AKAP12 AKT3 ALOX5 ANXA2 APLP2 APOBEC3G APP
BLNK BMI1 CASP3 CAV1 CCL5 CCND2 CD27 CD63 CD69 CD70 CD79A CD81 CD86 CHST2 CNR1 CREM CSDA
CSNK2A2 CTSB CUL5 DPP4 EED EGR1 EZH2 FCER2 FGFR1 FOS FRK FYN GSK3B H2AFX HDAC9 HIST1H3H
HIST2H2AA3 HSP90AA1 HSP90B1 IFNGR2 IGF1R IL10RA IL7 ILK INPP5D JAK1 LGALS1 LIG1 LMNA LPL MAP2K6
MAP4K4 MARCKS MGAT5 MIF MYL9 MYLK NAB1 NCOR2 NFE2L2 NOTCH2 OGT PAX3 PCNA PLD1 PRF1 PRKCA
PTCH1 PTEN RFC5 RPS6KA5 RRM1 RUNX3 SELL SELP SIAH1 SKI TCF3 TNF TNFRSF1B VDR CD74 ADM TGFBR3.
Active genes in this attractor state were: AFF1, APLP2, APP, BMI1, CD27, CD81, CD86, CREM, CUL5, EED, EZH2,
FYN, GSK3B, HIST2H2AA3, HSP90B1, IL10RA, ILK, MARCKS, MGAT5, RRM1, SKI
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to the evolution of the disease.
Under both conditions of perturbation, the overexpression of the gene FOS and TNF
showed important influence in the evolution over time of the system (Fig. 6). In both
cases the system reaches complex attractors in which the network oscillates among a
set of four states, i.e., the attractor of the network is a cycle. In these states the nodes
involved in regulation of CLL oscillate under states of OFF or ON, which affects the
course of the disease.Discussion
We applied a system approach by linking proteins interaction data with differentially
expressed genes of the IGVH status, the reconstructed PPI network allowed identified
critical genes, and given the stringent parameters applied, they represent only relation-
ships based on strong protein interactions. The topology of the reconstructed PPI net-
work followed the power-law of node degree distribution, a feature of true complex
biological networks. Therefore, the obtained network is a scale-free biological entity ra-
ther than a random network, indicating the presence of few nodes having a very high
degree measure [21]. On the other hand, it is recognized that high values of degree cen-
trality are associated with proteins that are interacting with several others suggesting a
central regulatory role [23]. The degree index highlighted some important proteins with
regulatory functions and considered interactions hubs in the PPI network: PTEN, FOS,
EGR1, TNF, TGFBR3, and IFGR2. According to the lethality and centrality rule, the
highly connected nodes are biologically relevant, representing vulnerable and essential
Inactive
Active
        2.99%                     2.45%                   2.99%                      2.72%                     2.72%                    2.99%   
Fig. 5 Major attractors obtained from 50 random initial states. The columns of the table represent
consecutive states of the attractor. On top, the percentage of states leading to the attractor is supplied.
Genes are encoded in the following order: AEBP1 AFF1 AICDA AKAP12 AKT3 ALOX5 ANXA2 APLP2
APOBEC3G APP BLNK BMI1 CASP3 CAV1 CCL5 CCND2 CD27 CD63 CD69 CD70 CD79A CD81 CD86 CHST2
CNR1 CREM CSDA CSNK2A2 CTSB CUL5 DPP4 EED EGR1 EZH2 FCER2 FGFR1 FOS FRK FYN GSK3B H2AFX
HDAC9 HIST1H3H HIST2H2AA3 HSP90AA1 HSP90B1 IFNGR2 IGF1R IL10RA IL7 ILK INPP5D JAK1 LGALS1 LIG1
LMNA LPL MAP2K6 MAP4K4 MARCKS MGAT5 MIF MYL9 MYLK NAB1 NCOR2 NFE2L2 NOTCH2 OGT PAX3
PCNA PLD1 PRF1 PRKCA PTCH1 PTEN RFC5 RPS6KA5 RRM1 RUNX3 SELL SELP SIAH1 SKI TCF3 TNF TNFRSF1B
VDR CD74 ADM TGFBR3
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stability of cancer cells through these hubs.
It was noted that highly connected proteins in the PPI network are not necessarily
represented for highly DEG. Consequently, genes with a central role in cancer not
detected for high-throughput approaches could be identified by networks based analysis
[6]. This was the case for PTEN, FOS, EGR1 and TNF, whose p values were significant
but they were not among the lowest in the meta-analysis. Several genes with known
prognostic implications in CLL were present in the list of DEG; additionally, the top
DEG obtained were consistent with other studies [32–34], validating these findings the
microarray meta-analysis approach to produce robust conclusions.
LPL is one for the strongest prognostic markers to predict outcome in CLL [35, 36].
It was one of the genes with high betweenness index, reflecting the large amount of
control exerted by this node over the interactions between the other nodes, in this way,
LPL may function as bridge between sub-graphs. According to Kolset and Salmivirta
[37] LPL facilitate the contact between monocytes and endothelial cell through its
union with heparan sulfate proteoglycans, serving as a bridging protein between cell
surface proteins and lipoproteins. On the other hand, LPL may influence CLL behavior
for its relation with functional pathways involved in fatty acid degradation and signaling
[38].
All genes found with high centralities have central roles in cancer and are involved in
major, diverse and sometimes interrelated signaling pathways. They have roles as tumor
suppressors or oncogenes, engaging central role in cancer progression. PTEN has
phosphatase catalytic function that antagonizes the PI3K/AKT signaling pathway and
ab
t=  1  2  3  4  
t=  1  2  3  4  
Inactive
Active
Fig. 6 Genes are encoded in the following order: AEBP1 AFF1 AICDA AKAP12 AKT3 ALOX5 ANXA2 APLP2
APOBEC3G APP BLNK BMI1 CASP3 CAV1 CCL5 CCND2 CD27 CD63 CD69 CD70 CD79A CD81 CD86 CHST2
CNR1 CREM CSDA CSNK2A2 CTSB CUL5 DPP4 EED EGR1 EZH2 FCER2 FGFR1 FOS FRK FYN GSK3B H2AFX
HDAC9 HIST1H3H HIST2H2AA3 HSP90AA1 HSP90B1 IFNGR2 IGF1R IL10RA IL7 ILK INPP5D JAK1 LGALS1 LIG1
LMNA LPL MAP2K6 MAP4K4 MARCKS MGAT5 MIF MYL9 MYLK NAB1 NCOR2 NFE2L2 NOTCH2 OGT PAX3
PCNA PLD1 PRF1 PRKCA PTCH1 PTEN RFC5 RPS6KA5 RRM1 RUNX3 SELL SELP SIAH1 SKI TCF3 TNF TNFRSF1B
VDR CD74 ADM TGFBR3. a. Visualization of states under overexpression of FOS b. Visualization of states
under overexpression of TNF
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tional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) super-
family, can induce a wide range of intracellular signal pathways including apoptosis and
cell survival as well as inflammation and immunity. TNF has two receptors (TNFR1,
TNFR2), TNFR1 signaling induces activation of many genes, primarily controlled by
two distinct pathways, NF-kappa B pathway and the MAPK cascade, or apoptosis and
necrosis. TNFR2 signaling activates NF-kappa B pathway, including PI3K-dependent
NF-kappa B pathway and JNK pathway leading to survival [40]. FOS gene family
encodes leucine zipper proteins that can dimerize with proteins of the JUN family,
thereby forming the transcription factor complex AP-1. As such, the FOS proteins have
been implicated as regulators of cell proliferation, differentiation, and transformation.
In some cases, expression of the FOS gene has also been associated with apoptotic cell
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and a transcriptional regulator. The products of target genes it activates are required
for differentiation and mitogenesis [42]. TGFBR3 is a membrane proteoglycan that
functions as a co-receptor with other transforming growth factors receptors. Soluble
TGFBR3 may inhibit TGFB signaling. Decreased expression of this receptor has been
observed in various cancers [41].
When the attractors found in the analysis of Boolean model are analyzed, several key
proteins associated with specific signaling pathways related with cancer are found, it
became clear that the phenotype depends upon multiple and interrelated signaling
pathways. We underscore the importance of MAPK signaling pathway, identified by
enrichment analysis, under FOS overexpression in the Boolean model. Belonging to the
MAPK/ERK signaling cascade were found activated: CASP3, FGFR1, AKT3, FOS,
MAP2K6, MAP4K4, PRKCA, RPS6KA5, and TNF. Aberrations in the MAPK/ERK
pathway have been identified in human cancers in high frequency including
hematologic malignancies [42]. In the context of CLL, the MAPK signaling pathway
has been recently implied in the disease based on clustering of RNA sequencing data
[43]. Similarly, working with gene co-expression subnetworks associated with disease
progression, it has been proven association of MAPK pathway with higher expression
levels in patients at early stages of the disease [44].
The regulatory hubs determine the behavior of the disease over time. The dynamics
of the network is controlled by attractors involved of diverse signaling pathways, which
may suggest a variety of mechanisms controlling the difference in CLL behavior. “The
2 distinct disease” hypothesis in CLL could be challenged; it is an interesting approach
to speculate that the CLL disease transcriptome evolves over time to reach a state
associated with disease requiring treatment [44]. These results have implications for
understanding transcriptional dynamic in the evolution of the disease.Conclusion
The PPI network and a Boolean model of IGVH mutational status in CLL allowed iden-
tified regulatory proteins and generated insight about processes associated with the mani-
fest differences in prognosis. The perturbation in the network through overexpression of
important regulatory proteins, such as FOS and TNF, determine the dynamic of the
network and activate genes involved in different signaling pathways that play important
roles in cancer.Methods
Differential expression analysis between the IGVH mutational statuses
To ensure reliability and generalization of results, we combined information from
different and independent microarray expression cohorts. It is well known that integra-
tion of expression data allow the discovery of new biological insights by increasing the
statistical power [45]. We retrieved CLL cohorts from the Gene Expression Omnibus
(GEO) of the National Center for Biotechnology Information (NCBI). The cohorts
selected (GSE2466, GSE16746, GSE9992 and GSE38611) had raw data available, were
originally processed with different microarray platforms and had at least 60 CLL
patients with information about the IGVH statuses, in total were processed 356 CLL
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using the VSN method implemented in R [46]. For filtering non-expressed and non-
informative genes, matching genes among different microarray platforms and merging
among studies, we used MetaDE package in R [47]. To combining the information of
cohorts and avoid batch effect we followed a meta-analysis approach, the moderated-t
statstics with permutations was used for individual analysis and Fisher P-value combin-
ation method for combine the individual p values [48]. For meta-analysis we used the
“MetaOmics” software suite [47].Reconstruction of protein–protein interaction network
The reconstruction of the protein–protein interaction network was based on data from
differential expression analysis between IGVH mutational statuses. The list of 502 DE
genes obtained was used to retrieve interacting partners from curated databases and
current literature.
The protein–protein interaction network was constructed based on the current litera-
ture and, through the STRING—Search Tool for the Retrieval of Interacting Genes/
Proteins—web source [49]. The STRING database contains information from several
sources, including experimental data, computational prediction methods, public text
collection and an recompilation of predicted protein interactions of databases such as
EXPASY [50], BIND [51], BioGRID [52], DIP [53], IntAct MINT [54], and HPRD [55]
and with interactions from the pathway databases such as PID [56], Reactome [57],
KEGG [58], and EcoCyc [59].
In order to reduce the amount of data while maintaining the main gene relations, the
parameters of confidence for STRING were restricted for obtain more reliable associa-
tions. Furthermore, the active prediction methods taken into account for STRING pre-
dictions were: co-expression, experiments, databases, and text mining. From the
protein-protein interactions predicted by STRING, with the restrictions mentioned
above, only the genetic relationships causing the activation or inhibition of the compo-
nents of the network were considered. In this way we reduced the number of network
nodes from 502 to 90. Is important to state that the database predictive methods could
reduce the overall confidence of network.
Network topology analysis
Topological analysis of the protein–protein interaction network was carried out by
plugin Network Analysis [60] of the open source program Cytoscape 3.1.0 [61].
A topological evaluation of the network was carried out by evaluating structural
parameters such as the clustering coefficient and degree distributions, to evaluate the
number of interactions among one node and its neighbors, normalized by the
maximum number of possible interactions, and to determine the number of nodes
directly connected (first neighbors) to a given node v, respectively. In the network
evaluation we distinguished in-degree distribution, when the edges target the node v,
and out-degree distribution, when the edges target the adjacent neighbors of v [62, 60].
The evaluation of the relevance of a protein in the PPI network was also made
through measurements of network centrality parameters, for this purpose, were used
the betweenness, closeness and degree metrics. On the other hand, to analyze the
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diameter, parameters that indicate how distant are the two most distant nodes, showing
the overall proximity between nodes in the interaction network analyzed [21].
Boolean network model
In a Boolean network model, each node i = 1, 2, …, N represents a protein of the net-
work that can assume only binary states θi. When θi = 1 the protein is functionally ac-
tive (TRUE), on the other hand, when θi = 0 the protein is functionally inactive
(FALSE). Thus, a network with N nodes will have 2 N possible states [21]. In this
model, edges represent regulatory relationships between elements; their orientation in the
network follows the direction of regulation process from the upstream to the downstream
node. As time passes, the state of each node is determined by the states of its neighbor,
through Boolean transfer functions based on evidence from the literature [63, 64].
The exponential behavior of the possible states in a Boolean network makes it com-
putationally unsuitable for large networks, where it is necessary to reduce the network
size, restricting the protein–protein interactions to the relationships of activation or
inhibition of any of the components of the system.
In this study, the Boolean synchronous algorithm proposed by Stuart Alan Kauffman
in 1969 [13] was implemented. The synchronous pattern is the most simple update
mode, where the states of all nodes are updated simultaneously according to the last
state of the network [15]. We used the package BoolNet [65] to construct Boolean
synchronous networks from knowledge of the dependencies of genes, based on
evidence from the current literature.
Starting from an initial condition, the model evolves over time to finally stabilize in a
recurrent state known as attractor, representing the long-term behavior of the system
[15]. Different initial conditions for the model may lead the system to different attrac-
tors, whereby the Boolean model should start from previously known biological infor-
mation; in this model the initial states of the network were determined from results
supplied for microarray analysis of up and down regulation states (Additional file 4:
Table S4). Aiming to prove the sensitivity of the Boolean model, we assayed 50 random
initial states, and demonstrated that the constructed model shows changes in the struc-
ture of the attractor achieved in the steady state under different initial states.
To determine critical proteins for structure and behavior of the system, we examined
the changes in network attractors if a certain component is knocked out (fixed in the
OFF state in the Boolean model) or overexpressed (fixed in the ON state in the Boolean
model). If knocking out or overexpressing a component leads to changes in network
dynamic response, it can be concluded that this component is implicated in the
biological regulation processes [15].
Functional enrichment analysis
Significant concurrent annotations from KEGG and Panther pathways were searched
with GeneCodis software [66–68].
Additional files
Additional file 1: Table S1. Summary of genes functions.
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Additional file 3: Table S3. Topological parameters for the individual nodes.
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